Amgen Inc. (NASDAQ:AMGN) Position Reduced by Asahi Life Asset Management CO. LTD.

Asahi Life Asset Management CO. LTD. lessened its stake in Amgen Inc. (NASDAQ:AMGNGet Rating) by 6.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 42,919 shares of the medical research company’s stock after selling 3,043 shares during the period. Amgen accounts for about 3.0% of Asahi Life Asset Management CO. LTD.’s portfolio, making the stock its 8th largest position. Asahi Life Asset Management CO. LTD.’s holdings in Amgen were worth $9,674,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently added to or reduced their stakes in the stock. FMR LLC grew its holdings in Amgen by 24.9% during the 2nd quarter. FMR LLC now owns 8,911,384 shares of the medical research company’s stock worth $2,168,140,000 after acquiring an additional 1,774,223 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Amgen by 1.1% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 8,819,690 shares of the medical research company’s stock valued at $2,132,778,000 after buying an additional 94,565 shares in the last quarter. State Farm Mutual Automobile Insurance Co. boosted its holdings in shares of Amgen by 1.4% in the 2nd quarter. State Farm Mutual Automobile Insurance Co. now owns 2,779,471 shares of the medical research company’s stock valued at $676,245,000 after buying an additional 37,200 shares in the last quarter. Federated Hermes Inc. boosted its holdings in shares of Amgen by 23.3% in the 2nd quarter. Federated Hermes Inc. now owns 1,831,164 shares of the medical research company’s stock valued at $445,522,000 after buying an additional 346,190 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in shares of Amgen by 279.3% in the 2nd quarter. Renaissance Technologies LLC now owns 1,439,745 shares of the medical research company’s stock valued at $350,290,000 after buying an additional 1,060,200 shares in the last quarter. Hedge funds and other institutional investors own 75.53% of the company’s stock.

Insider Activity at Amgen

In related news, SVP Nancy A. Grygiel sold 545 shares of Amgen stock in a transaction on Tuesday, November 8th. The shares were sold at an average price of $293.54, for a total value of $159,979.30. Following the sale, the senior vice president now owns 13,009 shares of the company’s stock, valued at approximately $3,818,661.86. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.46% of the stock is owned by corporate insiders.

Amgen Stock Performance

Shares of NASDAQ:AMGN traded down $0.45 during trading on Wednesday, hitting $259.25. 250,575 shares of the stock traded hands, compared to its average volume of 1,979,948. The company has a quick ratio of 1.35, a current ratio of 1.68 and a debt-to-equity ratio of 10.17. The company has a market cap of $138.33 billion, a price-to-earnings ratio of 20.83, a P/E/G ratio of 1.85 and a beta of 0.67. The company has a fifty day moving average price of $273.21 and a two-hundred day moving average price of $257.04. Amgen Inc. has a 52-week low of $214.39 and a 52-week high of $296.67.

Amgen (NASDAQ:AMGNGet Rating) last released its quarterly earnings results on Thursday, November 3rd. The medical research company reported $4.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.43 by $0.27. Amgen had a net margin of 25.96% and a return on equity of 287.23%. The firm had revenue of $6.65 billion for the quarter, compared to analysts’ expectations of $6.56 billion. During the same quarter last year, the company earned $4.67 EPS. The firm’s revenue for the quarter was down .8% compared to the same quarter last year. As a group, equities analysts predict that Amgen Inc. will post 17.62 EPS for the current year.

Amgen Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, March 8th. Investors of record on Wednesday, February 15th will be paid a $2.13 dividend. The ex-dividend date is Tuesday, February 14th. This represents a $8.52 dividend on an annualized basis and a yield of 3.29%. This is a boost from Amgen’s previous quarterly dividend of $1.94. Amgen’s dividend payout ratio (DPR) is currently 62.23%.

Analyst Ratings Changes

A number of analysts have recently weighed in on AMGN shares. Morgan Stanley raised their price target on shares of Amgen from $279.00 to $282.00 and gave the company an “overweight” rating in a report on Friday, November 4th. Wells Fargo & Company increased their price objective on shares of Amgen from $250.00 to $285.00 and gave the company an “equal weight” rating in a research report on Tuesday, January 3rd. StockNews.com raised shares of Amgen from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, January 17th. Truist Financial increased their price objective on shares of Amgen from $266.00 to $280.00 and gave the company a “hold” rating in a research report on Tuesday, November 8th. Finally, Oppenheimer increased their price objective on shares of Amgen from $300.00 to $310.00 and gave the company an “outperform” rating in a research report on Tuesday, December 6th. Four research analysts have rated the stock with a sell rating, four have issued a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $253.57.

Amgen Company Profile

(Get Rating)

Amgen, Inc is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA.

Featured Articles

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGNGet Rating).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.